title: Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
abstract: Administration of VP025 (Vasogen Inc.), a novel drug formulation based on phospholipid nanoparticles incorporating phosphatidylglycerol, has previously been shown to have a neuroprotective effect in the brain. We examined the effect of VP025 in a rat model of Parkinson's disease, the 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle. VP025 or phosphate-buffered saline (PBS) was administered to rats 14 days, 13 days and 1 day before the unilateral 6-OHDA lesion. Functional integrity of nigrostriatal dopaminergic neurons was assessed 7 and 21 days later by amphetamine-induced rotational testing and we observed that rotational counts were significantly less in rats that were pretreated with VP025 compared with PBS-pretreated 6-OHDA-lesioned rats. Neurochemical analysis at 10 and 28 days after lesion revealed that VP025 protected against a 6-OHDA-induced decrease in concentrations of striatal dopamine and its metabolites. Immunocytochemical studies of the ipsilateral substantia nigra showed that VP025 significantly inhibited 6-OHDA-induced loss of dopaminergic neurons. We also observed that increases in immunostaining for activated microglia and for activated p38 in dopaminergic neurons of 6-OHDA-lesioned rats were prevented by VP025. This study shows that VP025 has significant protective effects on the 6-OHDA-lesioned nigrostriatal pathway and may therefore have potential for the treatment of Parkinson's disease.
authors.affiliation: Vasogen Ireland Ltd, Dublin, Ireland.
authors.forename: S
authors.initials: S
authors.lastname: Crotty
authors.forename: P
authors.initials: P
authors.lastname: Fitzgerald
authors.forename: E
authors.initials: E
authors.lastname: Tuohy
authors.forename: D M
authors.initials: DM
authors.lastname: Harris
authors.forename: A
authors.initials: A
authors.lastname: Fisher
authors.forename: A
authors.initials: A
authors.lastname: Mandel
authors.forename: A E
authors.initials: AE
authors.lastname: Bolton
authors.forename: A M
authors.initials: AM
authors.lastname: Sullivan
authors.forename: Y
authors.initials: Y
authors.lastname: Nolan
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D008297:Male; D018696:Neuroprotective Agents / Q000737:chemistry / Q000627:therapeutic use*; D016627:Oxidopamine / Q000633:toxicity*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010715:Phosphatidylglycerols / Q000737:chemistry / Q000627:therapeutic use*; D010743:Phospholipids / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D018696:Neuroprotective Agents; D010715:Phosphatidylglycerols; D010743:Phospholipids; D016627:Oxidopamine